Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells

References

• MazzoliniGMurilloOAtorrasagastiCImmunotherapy and immunoescape in colorectal cancerWorld J Gastroenterol200713445822583117990348
   PubMed Web of Science ®Google Scholar
• BlattmanJNGreenbergPDCancer immunotherapy: a treatment for the massesScience2004305568120020515247469
   PubMed Web of Science ®Google Scholar
• MaceATHarrowSJGanlyIBrownSMCytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinomaActa Otolaryngol2007127888088717763002
   PubMed Web of Science ®Google Scholar
• ChalikondaSKivlenMHO’MalleyMEOncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase geneCancer Gene Ther200815211512518084242
   PubMed Web of Science ®Google Scholar
• RommelaereJGeletnekyKAngelovaALOncolytic parvoviruses as cancer therapeuticsCytokine Growth Factor Rev2010212–318519520211577
   PubMed Web of Science ®Google Scholar
• MoehlerMBlechaczBWeiskopfNEffective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectorsCancer Gene Ther20018315816711332986
   PubMed Web of Science ®Google Scholar
• MoehlerMSiebenMRothSActivation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1BMC Cancer20111146422029859
   PubMed Web of Science ®Google Scholar
• MalerbaMDaefflerLRommelaereJIggoRDReplicating parvoviruses that target colon cancer cellsJ Virol200377126683669112767988
   PubMed Web of Science ®Google Scholar
• MoehlerMHZeidlerMWilsbergVParvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cellsHum Gene Ther2005168996100516076257
   PubMed Web of Science ®Google Scholar
• van MierloGJBoonmanZFDumortierHMActivation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradicationJ Immunol2004173116753675915557168
   PubMed Web of Science ®Google Scholar
• ChanCWHousseauFThe ‘kiss of death’ by dendritic cells to cancer cellsCell Death Differ2008151586917948029
   PubMed Web of Science ®Google Scholar
• WangXBFanZZAntonDCTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentationBMC Immunol2011122121414236
   PubMed Web of Science ®Google Scholar
• ContardiEPalmisanoGLTazzariPLCTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interactionInt J Cancer2005117453855015912538
   PubMed Web of Science ®Google Scholar
• AlegreMLFrauwirthKAThompsonCBT-cell regulation by CD28 and CTLA-4Nat Rev Immunol20011322022811905831
   PubMed Web of Science ®Google Scholar
• RibasATumor immunotherapy directed at PD-1N Engl J Med2012366262517251922658126
   PubMed Web of Science ®Google Scholar
• RibasAHansonDCNoeDATremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancerOncologist200712787388317673618
   PubMed Web of Science ®Google Scholar
• PoirierNBlanchoGVanhoveBA more selective costimulatory blockade of the CD28-B7 pathwayTranspl Int201124121120964725
   PubMed Web of Science ®Google Scholar
• RibasAOvercoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206)Oncologist200813Suppl 4101519001146
   PubMed Web of Science ®Google Scholar
• AsciertoPAMarincolaFMRibasAAnti-CTLA4 monoclonal antibodies: the past and the future in clinical applicationJ Transl Med2011919622077981
   PubMed Web of Science ®Google Scholar
• OderupCCederbomLMakowskaACilioCMIvarsFCytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppressionImmunology2006118224024916771859
   PubMed Web of Science ®Google Scholar
• ZhuQLiuJYYangCMInfluence of antitumor drugs on the expression of Fas system in SW480 colon cancer cellsEur J Gastroenterol Hepatol200618101071107716957513
   PubMed Web of Science ®Google Scholar
• MoehlerMZeidlerMSchedeJOncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cellsCancer Gene Ther200310647748012768193
   PubMed Web of Science ®Google Scholar
• BilliauAInterferon-gamma: biology and role in pathogenesisAdv Immunol199662611308781267
   PubMed Web of Science ®Google Scholar
• IsaacsALindenmannJVirus interference. I. The interferonProc R Soc Lond B Biol Sci195714792725826713465720
   PubMed Web of Science ®Google Scholar
• SiebenMSchäferPDinsartCGallePRMoehlerMActivation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1Int J Cancer2013132112548255623151948
   PubMed Web of Science ®Google Scholar
• NencioniABrossartPNew perspectives in dendritic cell-based cancer immunotherapyBioDrugs2001151066767911604048
   PubMed Web of Science ®Google Scholar
• BallestreroABoyDMoranECirmenaGBrossartPNencioniAImmunotherapy with dendritic cells for cancerAdv Drug Deliv Rev200860217318317977615
   PubMed Web of Science ®Google Scholar
• KoidoSHaraEHommaSFujiseKGongJTajiriHDendritic/tumor fusion cell-based vaccination against cancerArch Immunol Ther Exp (Warsz)200755528128718219758
   PubMed Web of Science ®Google Scholar
• IidaTOhnoHNakasekoCRegulation of cell surface expression of CTLA-4 by secretion of CTLA-4-containing lysosomes upon activation of CD4+ T cellsJ Immunol200016595062506811046036
   PubMed Web of Science ®Google Scholar
• QureshiOSZhengYNakamuraKTrans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4Science2011332602960060321474713
   PubMed Web of Science ®Google Scholar
• KormanAJPeggsKSAllisonJPCheckpoint blockade in cancer immunotherapyAdv Immunol20069029733916730267
   PubMed Web of Science ®Google Scholar
• WalletMASenPTischRImmunoregulation of dendritic cellsClin Med Res20053316617516160071
   PubMedGoogle Scholar
• ChungKYGoreIFongLPhase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancerJ Clin Oncol201028213485349020498386
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• SchurichAKhannaPLopesARRole of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infectionHepatology20115351494150321360567
   PubMed Web of Science ®Google Scholar
• YinYWuCSongJDNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kineticPLoS One201167e2252421799884
   PubMed Web of Science ®Google Scholar
• SuneethaPVPischkeSSchlaphoffVHepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infectionHepatology201255369570822006345
   PubMed Web of Science ®Google Scholar
• RaziorrouhBUlsenheimerASchrautWInhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infectionGastroenterology20111414142214311431 e1621763239
   PubMed Web of Science ®Google Scholar
• HryniewiczABoassoAEdghill-SmithYCTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaquesBlood2006108123834384216896154
   PubMed Web of Science ®Google Scholar
• von EuwEChodonTAttarNCTLA4 blockade increases Th17 cells in patients with metastatic melanomaJ Transl Med200973519457253
   PubMed Web of Science ®Google Scholar
• SuarezNAlfaroCDubrotJSynergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivoInt J Cancer2011129237438620853321
   PubMed Web of Science ®Google Scholar
• KatzJBMullerAJPrendergastGCIndoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escapeImmunol Rev200822220622118364004
   PubMed Web of Science ®Google Scholar
• SchroderKHertzogPJRavasiTHumeDAInterferon-gamma: an overview of signals, mechanisms and functionsJ Leukoc Biol200475216318914525967
   PubMed Web of Science ®Google Scholar
• van HorssenRTen HagenTLEggermontAMTNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utilityOncologist200611439740816614236
   PubMed Web of Science ®Google Scholar
• FuldaSDebatinKMSignaling through death receptors in cancer therapyCurr Opin Pharmacol20044432733215251124
   PubMed Web of Science ®Google Scholar
• FuldaSDebatinKMDeath receptor signaling in cancer therapyCurr Med Chem Anticancer Agents20033425326212769771
   PubMedGoogle Scholar
• SaidEADupuyFPTrautmannLProgrammed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infectionNat Med201016445245920208540
   PubMed Web of Science ®Google Scholar
• GajewskiTFFitchFWAnti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clonesJ Immunol198814012424542522967332
   PubMed Web of Science ®Google Scholar
• DaudelinJFMathieuMBouletSLabrecqueNIL-6 production by dendritic cells is dispensable for CD8(+) memory T-cell generationBiomed Res Int2013201312618923484075
   PubMed Web of Science ®Google Scholar
• RibasAComin-AnduixBChmielowskiBDendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanomaClin Cancer Res200915196267627619789309
   PubMed Web of Science ®Google Scholar
• HeoJReidTRuoLRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med201319332933623396206
   PubMed Web of Science ®Google Scholar
• GeletnekyKHuesingJRommelaereJPhase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocolBMC Cancer2012129922436661
   PubMed Web of Science ®Google Scholar